Granulocyte-Colony Stimulating Factor (G-CSF) in Stroke Patients with Concomitant Vascular Disease—A Randomized Controlled Trial by Floel, Agnes et al.
Granulocyte-Colony Stimulating Factor (G-CSF) in Stroke
Patients with Concomitant Vascular Disease—A
Randomized Controlled Trial
Agnes Floel
1,2,3*
., Tobias Warnecke
4., Thomas Duning
4, Yvonne Lating
4, Jan Uhlenbrock
4, Armin
Schneider
5, Gerhard Vogt
5, Rico Laage
5, Winfried Koch
6, Stefan Knecht
4, Wolf-Ru ¨diger Scha ¨bitz
7*
1Department of Neurology, Charite ´-Universita ¨tsmedizin Berlin, Berlin, Germany, 2Center for Stroke Research Berlin, Charite ´-Universita ¨tsmedizin Berlin, Berlin, Germany,
3Cluster of Excellence NeuroCure, Charite ´-Universita ¨tsmedizin Berlin, Berlin, Germany, 4Department of Neurology, University of Mu ¨nster, Mu ¨nster, Germany, 5SYGNIS
Bioscience, Heidelberg, Germany, 6HAAPACS GmbH, Schriesheim, Germany, 7Department of Neurology, Bethel, Evangelisches Krankenhaus Bielefeld (EVKB), Bielefeld,
Germany
Abstract
Background: G-CSF has been shown in animal models of stroke to promote functional and structural regeneration of the
central nervous system. It thus might present a therapy to promote recovery in the chronic stage after stroke.
Methods: Here, we assessed the safety and tolerability of G-CSF in chronic stroke patients with concomitant vascular
disease, and explored efficacy data. 41 patients were studied in a double-blind, randomized approach to either receive 10
days of G-CSF (10 mg/kg body weight/day), or placebo. Main inclusion criteria were an ischemic infarct .4 months prior to
inclusion, and white matter hyperintensities on MRI. Primary endpoint was number of adverse events. We also explored
changes in hand motor function for activities of daily living, motor and verbal learning, and finger tapping speed, over the
course of the study.
Results: Adverse events (AEs) were more frequent in the G-CSF group, but were generally graded mild or moderate and
from the known side-effect spectrum of G-CSF. Leukocyte count rose after day 2 of G-CSF dosing, reached a maximum on
day 8 (mean 42/nl), and returned to baseline 1 week after treatment cessation. No significant effect of treatment was
detected for the primary efficacy endpoint, the test of hand motor function.
Conclusions: These results demonstrate the feasibility, safety and reasonable tolerability of subcutaneous G-CSF in chronic
stroke patients. This study thus provides the basis to explore the efficacy of G-CSF in improving chronic stroke-related
deficits.
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Citation: Floel A, Warnecke T, Duning T, Lating Y, Uhlenbrock J, et al. (2011) Granulocyte-Colony Stimulating Factor (G-CSF) in Stroke Patients with Concomitant
Vascular Disease—A Randomized Controlled Trial. PLoS ONE 6(5): e19767. doi:10.1371/journal.pone.0019767
Editor: Christoph Kleinschnitz, Julius-Maximilians-Universita ¨tW u ¨rzburg, Germany
Received February 2, 2011; Accepted April 4, 2011; Published May 23, 2011
Copyright:  2011 Floel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Deutsche Forschungsgemeinschaft (to A. F.: Fl 379-4/2, Fl 379-8/1; and by DFG-Exc 257), the
Interdisciplinary Center of Clinical Research Mu ¨nster (Floe3/004/08), and the Bundesministerium fu ¨r Bildung und Forschung (FKZ 0315673A and 01EO0801). G-CSF
was provided by SYGNIS Bioscience, Heidelberg, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: AS, RL, GV are employees of SYGNIS Bioscience GmbH. WK is employee of HAPAACS. This was an investigator-initiated trial, and SYGNIS
Bioscienceprovidedstudymaterial,butwasnotinvolved intrialdesign,studyprotocolgeneration,studyconduct,orregulatoryissues.AS,RL,GV and WKwereinvolved
in generating the statistical analysis plan, and conducted statistical analysis of trial outcome. AS, WRS are inventors on a number of patent applications claiming the use
of G-CSF for neurological diseases including stroke. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: agnes.floeel@charite.de (AF); wolf.schaebitz@evkb.de (W-FS)
. These authors contributed equally to this work.
Introduction
Stroke is the leading cause of adult disability in the United
States and Western Europe. Two thirds of stroke survivors suffer
from residual neurological deficits and have to cope with chronic
motor and language dysfunctions. So far, we have very limited
effective therapies in spite of intensive research efforts and nu-
merous clinical trials [1,2].
Basic science has improved our understanding of the mecha-
nisms underlying recovery of function following brain injury, and
started to identify strategies to facilitate these mechanisms, an
important one being intensive training [3]. However, training-
based interventions have so far provided only partial improve-
ments. Limited improvement with training alone may be due to
advanced age [4] and cerebral white matter lesions that lead to
functional disconnection of white matter tracts in the brain [5].
Both conditions are common in the stroke population [6].
Pharmacological agents seem to be attractive tools to facilitate
the beneficial effects of training-based interventions on recovery
[7]. Substances only recently discussed in the context of stroke
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19767rehabilitation are neural growth factors like Granulocyte-colony-
stimulating factor (G-CSF). G-CSF, a glycoprotein known to
promote differentiation in the granulocytic lineage, has long been
used in the clinic to counteract neutropenia and mobilize
hematopoietic stem cells from the bone marrow in stem cell
transplantation [8]. New data from cell culture studies and animal
models of stroke have shown that G-CSF, systemically given, passes
the intact blood-brain barrier and acts on neurons [8]. Importantly
for the recovery phase, G-CSF not only counteracts cell death, but
also exerts neuroprotective and neuroplasticity-enhancing proper-
ties, even when given at delayed time intervals [8–11]. Thus, GCSF
may have the potential to enhance neuroplasticity leading to
functional recovery even at long intervals after stroke [8,12].
Adverse events (AEs) related to low-dose application of G-CSF in
non-oncological individuals generally are only mild to moderate,
including bone pain, headache, myalgias, fatigue, nausea, insomnia,
and redness at the injection site. However, rare cases of potentially
life-threatening conditions like splenic rupture, acute lung injury,
vascular events, and exacerbation of autoimmune conditions have
been reported [13]. The elevation of leukocytes, intrinsic to G-CSF
treatment, may potentially lead to endothelial and blood coagula-
tion activation causing a plugging of the microvasculature close to
the infarction with an increased risk for thromboembolic events in
stroke patients [13]. On the other hand, a decrease in platelet count
might predispose to hemorrhagic events [13].
Inthepresentstudy,ourmainaimwasthereforetoassessthesafety
of G-CSF in a cohort of chronic stroke patients. Patients were chosen
to reflect the stroke population with regard to age, concomitant
diseases like hypertension, diabetes, and generalized atherosclerosis,
as well as their cerebral disease sequelae, like white matter
hyperintensities (WMH). We also explored the impact of G-CSF
on hand motor function for activities of daily living, motor and verbal
learning, and finger tapping speed, (secondary efficacy endpoints).
Methods
The protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol S1.
Ethics Statement
The study, conducted according to ICH GCP guidelines and
to the principles expressed in the Declaration of Helsinki, and
approved by the local ethics committee of the University of
Mu ¨nster and the German Federal Institute for Drugs and Medical
Products, and subsequently registered on ClinicalTrials.gov
(NCT00298597).
Patient population
Fourty-one individuals (48–85 years, mean 6868; 13 women)
gave written informed consent and participated in this double-
blind, placebo-controlled and randomized study. All patients
received study medication for at least two days. The safety
population thus consists of all 41 subjects. From two patients, no
efficacy data were obtained. Thus, the full analysis set (FAS)
consists of 39 subjects.
Patients were recruited at least 4 months after having presented
to the local stroke unit with an ischemic stroke, and MR-imaging
of the brain had shown the presence of WMH. Severity of WMH
was rated according to the validated score of Fazekas and
colleagues [14] that has been widely employed in previous studies
on white matter lesions in humans [15–17]: 0= no WMH, 1=
punctate foci of WMH, 2= beginning confluence of foci of
WMH, and 3= large confluent areas of WMH. Of the 85 patients
that were thus eligible and agreed to participate, 41 fulfilled the
additional study entry criteria: (1) No contraindications to G-CSF
treatment (2) No severe and untreated medical conditions; (3)
Mini-Mental State Examination .26; (4) Partial recovery from
initial deficit, so experimental tasks that included fine hand motor
function (Jebsen-Taylor Test) as well as a 5-finger motor sequence
task could be performed; (5) Right-handedness (for further details
on patients, see Table 1, Fig. 1). Demographic and stroke-specific
baseline characteristics were similarly distributed between G-CSF
and placebo groups.
All patients were evaluated neuropsychologically in a separate
session before G-CSF administration, using tests of general
intellectual function, attention, verbal fluency, digit spans, and
Table 1. Patient Demographics.
Parameter G-CSF Placebo significance
Age in years 66.468.9 69.967.2 n. s.
Gender (male/female) 14/7 14/6 n. s.
Years of education 12.263.1 11.762.3 n. s.
Fazekas-score 1.360.5 1.360.6 n. s.
Weeks since stroke 52.9612.1 64.0636.0 n. s.
NIHSS 1.261.1 1. 261.5 n. s.
Modified Rankin scale 1.2+0.8 1.3+1.1 n. s.
Lesion side (left/right) 10/11 9/11 n. s.
Arterial hypertension 18 16 n. s.
Diabetes mellitus 6 5 n. s.
At least one additional vascular risk factor (Hypercholesterolemia,
coronary heart disease, peripheral arterial occlusive disease)
15 16 n. s.
Blood pressure (systolic/diastolic) [mmHg] at baseline 131/78615.6/12.3 135/81615.6/9.0 n. s.
heart rate [beats/minute] at baseline 72614.3 72611.7 n. s.
body temperature [uC] at baseline 35.960.5 36.060.4 n. s.
n. s.: not significant; NIHSS: National Institutes of Health Stroke Scale; mean 6 SD given; significance determined by t-test, Mann-Whitney, or chi
2 test as appropriate.
doi:10.1371/journal.pone.0019767.t001
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study from June 2006 to August 2008.
Study medication
Study medication, and randomization to either G-CSF or
placebo, was provided by the pharmacy of the University of Mainz.
Filgrastim (recombinant human G-CSF produced in E. coli,
solubilised in a buffer containing 10 mM acetic acid, 5% (m/v)
sorbitol, 0.004% Tween 80, ph adjusted to 4.0 with NAOH), or
saline as placebo were filled in identical-looking glass vials to ensure
blinding. Treatment was then administered by the study nurse.
Results of blood analysis and potentially medically necessary actions
triggered by elevated leukocyte counts were exclusively accessible to
study investigators who did not take part in testing and analysis of
efficacy parameters, or rating of adverse events.
Study outline
Patients underwent neuropsychological testing and familiariza-
tion in all tasks one to three days before receiving the first dose of
G-CSF or placebo. Then, each participant was given either G-
CSF (10 mg/kg body weight/day), or saline solution (placebo,
0.1 ml/kg body weight/day), each administered as daily s. c.
injections over 10 days. This dose is in line with literature safety
data for healthy human bone marrow donors [18]. Vital signs and
laboratory parameters were determined repeatedly throughout the
course of the study (see Fig. 2 for details). Additionally, the trial
assessed the efficacy of G-CSF versus placebo on motor hand
functions in hand activities of daily living, motor and verbal
learning, and finger tapping speed.
Efficacy parameters
To assess motor hand functions, the Jebsen Taylor Test (JTT)
was employed [19]. This test has been widely used to assess a
broad range of hand functions required for activities of daily living,
has good validity and reliability, and has been extensively used in
rehabilitative settings [19–21]. Six subtests were performed:
Turning over cards, picking up small objects and placing them
in a can, picking up small objects with a teaspoon and placing
them in a can, stacking checkers, moving large light, and moving
large heavy cans. Dependent variable was total time to complete
the six subtests.
To assess motor learning, we used the serial reaction time task in
a modified version with a probabilistic instead of a deterministic
sequence to ensure the procedural task nature [22,23] (15%
random and 85% sequential elements in each block). Patients sat
in front of a 14-inch monitor with their right hand placed on a
special keypad with 5 different keys, one for each finger. Following
the rules of a finite-state grammar [22,23], one of the black squares
Figure 1. Flowchart of study. Shown is a flowchart of the trial with the number of patients in the different study populations (safety and FAS (full
analysis set)).
doi:10.1371/journal.pone.0019767.g001
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the corresponding keys as fast as possible. The task consisted of 2
blocks of 500 key-presses each. Dependent variable was difference
in reaction times between random and sequential elements.
To assess verbal learning, a word learning model was employed
that mimics vocabulary acquisition in healthy individuals, and is
relevant to language reacquisition in stroke patients with aphasia
[24,25]. Patients had to indicate by button presses whether they
deemed a particular coupling to be correct or incorrect. The
underlying learning principle was higher statistical co-occurrences
of certain couplings as compared with other pairings. Participants
were trained for five days, each day about 50 minutes. Details of
the training program are described elsewhere [24]. Dependent
variables were percentage of correct responses and reaction times.
To assess finger tapping speed, patients performed a fast finger-
tapping task [26]. Patients were instructed to press a key with the
right index fingerasquicklyaspossible fora total of10 seconds.The
task was repeated three times, with 1-minute resting intervals
between trials. The keypad was connected to a laboratory computer
that recorded the frequency of tapping (dependent variable).
Statistical analysis
Sample size was derived from the AXIS I study [27], and from
similar studies using experimental treatments in chronic stroke
patients [28,29]. Primary endpoint was the total number of
adverse events (AEs), as a function of group (unpaired t-test).
Secondary safety endpoints were number of treatment-related
adverse events (AEs), discontinuation due to treatment-related
AEs, laboratory parameters including leukocyte, erythrocyte, and
platelet count, and vital signs (body temperature, blood pressure,
heart rate). Judgment of causality was conducted by an in-
vestigator of the trial (WRS). According to the study protocol, the
following points were considered: 1) Known pharmacology of G-
CSF; 2) Side effects described in the product information of G-
Figure 2. Time schedule of procedures and tests performed. Shown are the different test series performed over 38 days.
doi:10.1371/journal.pone.0019767.g002
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to treatment with G-CSF. The safety population consisted of all
subjects who received at least one dose of study medication
(n=41).
Additionally, secondary efficacy endpoints were explored, that is,
the changes from Day 3 to mean of Day17 and Day 38 for JTTand
finger tapping speed, as well as success in verbal and motor learning
during the second week of treatment, as a function of group. Here,
the pre-defined primary efficacy endpoint was the JTT. The
analyses were performed in the full analysis set according to
guideline ICH E9 (FAS) population, which was defined as all
subjects who received at least one dose of study medication, had a
baseline evaluation, and at least one evaluation after the start of the
treatment (n=39). Last observations were carried forward in the
endpoint analysis (LOCF). Analysis of covariance with adjustments
forage,timesinceinfarction,location,lesionsize,and baselinevalue
was performed for the efficacy variables. Significance for all tests
was set at p,0.05. All data are expressed as means 6 SEM, unless
stated otherwise. All statistical analyses were performed using SPSS
16, JMP 8.01, or SAS 9.1.
Results
Subjects included in analyses
All 41 subjects originally recruited into the study took at least
two doses of study medication (safety population). Two patients
that received at least one dose of study medication had to be
excluded, one of them due to acute disease unrelated to the study
(bronchitis), the other withdrew consent without specific reason.
Thus, 39 subjects remained for the efficacy analyses (see Figure 1,
flowchart of patient populations).
Safety analysis: Adverse events
All patients (n =41) received at least one dose of study
medication. In general, the study medication was tolerated well. In
three patients receiving verum the dose was halved at day 10 (2) or
day 3 (1) due to leukocyte count .50/nl without clinical
symptoms. In three patients medication was halted at day 9 (2)
or day 8 (1) due to leukocyte count .70/nl without clinical
symptoms. In two patients verum medication was stopped at day 3
or day 5 due to bronchitis and headache cum nausea, respectively.
One patient received dosing every second day starting at day 4 due
to development of bone pain that was manageable under this
regimen.
Three patients in the G-CSF group (3/21) and one patient in
the placebo group (1/20) suffered from serious AEs (SAEs), none
of which was judged to be related to study medication. These
SAEs were: Pons infarction, bronchitis, bone fracture, and
infection with unclear source. The number of patients in each
group with at least one AE was 17/21 in the G-CSF and 14/20 in
the placebo group (Fisher’s Exact Test, p=0.48). The total
Table 2. All adverse events, listed by system organ class (n=21 in the G-CSF, n=20 in the placebo group.
Side effects AEs Patients with AEs
Placebo G-CSF Placebo G-CSF
Nervous system disorders 17 14 11 10
General disorders and administration site conditions 8 15 5 10
Musculoskeletal and connective tissue disorders 3 7 2 7
Gastrointestinal disorders 1 8 1 5
Psychiatric disorders 0 7 0 5
Respiratory, thoracic and mediastinal disorders 0 4 0 4
Infections and infestations 1 2 1 2
Skin and subcutaneous tissue disorders 3 0 3 0
Vascular disorders 1 1 1 1
Eye disorders 1 0 1 0
Investigations 1 0 1 0
Surgical and medical procedures 1 0 1 0
doi:10.1371/journal.pone.0019767.t002
Table 3. All treatment-related adverse events (probable or possible), listed by system organ class (n=21 in the G-CSF, n=20 in the
placebo group).
Side effects Events Patients
Placebo G-CSF Placebo G-CSF
General disorders and administration site conditions 81 5 51 0
Nervous system disorders 71 2 58
Musculoskeletal and connective tissue disorders 1616
Investigations 1010
Skin and subcutaneous tissue disorders 1010
doi:10.1371/journal.pone.0019767.t003
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Test p=0.055). AEs in the G-CSF group were more often related
to the treatment itself: 33/58 (59%) events reported in the G-CSF
group were classified as likely related to the treatment, versus 18/
37 (49%) in the placebo. This effect revealed a strong trend for
more related events in the G-CSF group when comparing absolute
numbers (Chi Square Test p=0.054). All treatment-related events
were rated in their severity as mild or moderate, and were within
the known side effect profile of G-CSF treatment, most often
headache (n=9), fatigue (n=9), malaise (n =6), back pain (n=5),
limb discomfort (n=3), and abdominal pain (n=1). Nausea (n
=4), and sleep disorders (n=7) were rated as not treatment-
related; other side effects occurred with a frequency of,2. Most
frequent side effects in the placebo group included headache
(n=7), fatigue (n=8), and dizziness (n=5). For further informa-
tion on adverse events, please refer to Table 2 and 3. In
conclusion, a higher number of mild to moderate AEs related to
treatment were observed in the G-CSF group, explained by the
known side effect profile of this growth factor.
Safety analysis: Vital signs and laboratory values
Analysis of blood pressure, heart rate, and body temperature
revealed no significant difference between groups at baseline, at
Study Days 6–10, Study Day 17, or 38.
We measured G-CSF values at day 0, days 4 or 5; days 8 or 9,
and day 12/13. G-CSF levels in the verum group rose from
9.2662.42 pg/ml serum at baseline to 306.076106.81 pg/ml at
day 4, and were already back to 37.83 613.68 pg/ml at day 12/
13 (Figure 3a).
As expected, leukocyte count showed a significant increase in
the verum group, from mean 7.5/nl at baseline to a mean value of
41.9/nl on day 8. Highest leukocyte count, reached in one patient
on day 8, was 75.4/nl. At day 17 (7 days after last administration
of G-CSF/placebo) values were back to normal (mean 7.426
0.72/nl for G-CSF vs. 6.9460.34/nl for placebo (Figure 3b).
We observed an anticipated drop in platelet count, with a
decline starting on study day 2, reaching its lowest count on study
Day 10, and returning to baseline on study day 17 (Figure 3c). The
difference between treatment groups became significant from day
8 to 12 (all p’s,0.008). Lowest platelet count was reached at day
10 with 158.2669.94 thrombocytes/nl.
For erythrocyte count, no major difference between treatment
groups was found (Figure 3d).
Influences on motor and cognitive measures
Patients included in the efficacy analysis were able to perform all
four behavioural tasks. Behaviour of treatment groups over time in
tests for JTT, motor learning, verbal learning, and finger tapping
speed appeared similar (Figure 4a–d). As the pre-defined primary
efficacy endpoint, difference between G-CSF and placebo in
change from JTT at Day 3 to study end point (mean of Day 17
and 38) did not reveal a significant effect of treatment (6.0 s60.9 in
the G-CSF group, 5.5 s60.8 in the placebo group). Number of
errors was likewise comparable between groups (t-test, ns). In an
extended exploratory statistical model including covariates age,
time since infarction (statistically significant), lesion size, side of
infarction, and JTT at Day 3, a similar result emerged for
difference between treatment groups (p=0.36). Our primary
endpoint for exploratory efficacy analysis was therefore negative.
Discussion
The present study shows that subcutaneous G-CSF treatment in
elderly chronic stroke patients with concomitant vascular disease is
safe and reasonably well tolerated. Analysis of exploratory motor
and cognitive measures did not detect significant effects of
treatment in the pre-specified analyses.
So far, only data on two randomized controlled trials with G-
CSF application in stroke patients are available [30]. A trial in
acute stroke patients (AXIS) demonstrated the safety of a 3-day
course of high-dose G-CSF, administered intravenously [27].
Incidence of thromboembolic events and distribution of AEs were
similar between treatment groups, and no negative influence on
the development of vessel occlusion or stenosis from baseline to
end of treatment was noted. Thus, the concern about harmful
effect on vessel walls raised previously [31] was not substantiated.
Two previous pilot studies in acute and subacute stroke patients
likewise suggested safety of G-CSF treatment [30,32].
Our study is the first randomized controlled trial that assessed
the safety and feasibility of G-CSF in chronic stroke patients, over
an extended administration period (10 days). Numbers of all AEs,
and of likely related AEs, the primary endpoint aimed at safety,
were more frequent in the G-CSF group although this difference
failed formal significance. However, this is not unexpected given
the known side effect spectrum of G-CSF, especially with the
longer time frame of administration in comparison to the recent
AXIS trial. Importantly, AEs with likely relationship to study
medication were always rated as mild to moderate, and all
involved well-known side effects from G-CSF. In two patients,
likely related adverse events (bone pain and headache cum nausea)
led to intermittent dosing or to discontinuation of study
medication.
A rise in leukocytes is the main expected effect of G-CSF outside
the central nervous system. Leukocytes reached an average
maximum of 42/nl at day 8, and dropped back to baseline levels
less than one week after end of treatment. Although no clinical
data exist that ascribe harmful effects to an isolated, G-CSF-
triggered rise in leukocytes, we halved dosing at leukocyte counts
.50/nl, and halted dosing at values .70/nl.
Similar to the study in acute stroke (AXIS), the rise in leukocytes
did not lead to an increase in thromboembolic events. It is
reassuring that so far no clinical evidence suggests a G-CSF
treatment-related adverse effect on the cerebral microvasculature
assessed in almost hundred stroke patients [27,30,31]. This
observation is backed by a recent animal study revealing no
evidence for microvascular plugging or thrombembolic adverse
events despite a significant rise of white blood cells in the peri-
ischemic microcirculation [33].
Apart from the rise in leukocytes, a lowering in platelets was
noted, which is a known side effect of G-CSF treatment also in
other patient populations. Thrombocyte counts did rapidly
recuperate to normal levels 7 days after end of G-CSF treatment.
However, in future studies with chronic G-CSF treatment this
Figure 3. G-CSF levels and hematological parameters. a, serum concentrations of G-CSF measured at 4 time points throughout the study. Two
days after the end of treatment (day 12/13) levels have returned to normal. Levels were measured at day 0, day 4 or 5, day 8 or 9, and day 12 or 13. b-
c, hematological parameters. b, Leukocytes are already elevated at day 2, and reach their peakk at day 8. 7 days after end of medication levels have
returned to normal (day 17). Error bars indicate standard errors of the mean (SEM). c, Thrombocyte counts decrease under G-CSF treatment. Lowest
numbers are reached by day 10. Numbers normalize 7 days after end of treatment. d, No influence of treatment on erythrocyte numbers was
detected.
doi:10.1371/journal.pone.0019767.g003
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receiving anticoagulation or platelet aggregation blockers.
In summary, the present study suggests safety and reasonable
tolerability of G-CSF application over the course of 10 days, even
in the vulnerable population of elderly stroke patients with
concomitant diseases like hypertension, diabetes, and WMH,
known to increase morbidity and mortality [34]. This finding is in
line with the data from 20 years of clinical oncological experience
with G-CSF that has demonstrated an excellent clinical safety
profile for the substance (see [18] for review).
However, it needs to be clarified if higher elevation of leukocyte
count than 50 – 70/nl can be tolerated in chronic application, and
lowering of platelets needs to be closely monitored.
We have conducted a broad array of tests in view of
demonstrating feasibility of such a trial approach, but also with
the aim to explore possible efficacy signals. The tests explored did
not show a meaningful difference between G-CSF and placebo,
including the Jebsen-Taylor test (JTT), chosen as primary efficacy
parameter.
Several reasons may be responsible for the failure to detect
clearer signals of efficacy in our study. First, the current small
study is certainly underpowered to show effects in a highly
heterogeneous population as the one examined here. This is
underlined by a retrospective power analysis: We had a 25%
chance of detecting a 25% effect size in the main outcome
parameter, change in JTT from day 3 to mean of day 17 and day
38 (population change=6.1 points63.6 SD), and an 8% chance to
detect an effect size of 10%. A sample size of 176 is needed to
detect a 25% effect size with a power of 80%. Second, we chose
patients that had almost completely recovered from their initial
deficits, and were therefore able to participate in the experimental
tasks. However, some patients were more than a year away from
their stroke, and larger effects of G-CSF may have been present if
G-CSF had been given at an earlier stage [9]. Third, patients had
to perform the task always with their dominant right hand, thus
avoiding an interaction of intervention effect with handedness
[23,35]. Fourth, with the primary focus to assess safety of G-CSF
in chronic stroke, the study included patients with different lesion
sizes (lacunar, small territorial) and sides (right and left) and
different time intervals from the stroke event. These particulars of
the study design might have contributed to diluting a possible
beneficial effect of G-CSF on learning in the verbal or the motor
domain, or motor function. Future studies on efficacy should
therefore include a more homogeneous patient cohort, and be
conducted at an earlier state after stroke. Note also that hand
motor function had its ‘‘baseline assessment’’ on day 3 only, and
motor and verbal learning were assessed during the second week of
treatment, to detect differences in learning ability under G-CSF
versus placebo. A significant difference between treatments may
have emerged if baseline assessment of hand motor function had
been conducted at day 0, or pre-treatment learning had been
compared with learning during treatment for both G-CSF and
Figure 4. Exploratory efficacy outcome measures. a, motor
learning task: Magnitude of learning is reflected by the difference in
reaction times between random and sequential elements [ms]. B,
Jebsen Taylor Test of hand function: Performance in this test was
reflected by total time needed to complete the six subtests [s]. c, verbal
learning task: Magnitude of learning is reflected by the [percentage] of
correct responses (words learned). D, finger tapping speed: Perfor-
mance in this test was reflected by the [number of key presses] within
the time interval. Curves were fitted using a cubic spline function with a
lambda of 0.05.
doi:10.1371/journal.pone.0019767.g004
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studies.
Concomitant white matter lesions might also have complicated
benefit assessment in our population: Efficient communication in
the human brain relies on the integrity of white matter tracts
[36,37], and severity of WMH is negatively associated with
rehabilitation succession in neurological disease [38], possibly due
to disconnection of cerebral circuits, reduced vascular density and
cerebral blood flow, and impaired synaptic plasticity (see [38] for
review).
Apart from particular limitations of the study cohort and power
issues, questions of dosing and timing are evident. Higher doses
should be included in the next trial, as an increase of effect size
seems to occur with dose in acute stroke patients (AXIS). Also, a
longer time period or repeated dosing intervals may be needed to
see sustained effects.
In summary, the present study is a further indication that G-
CSF administration is safe and reasonably well-tolerated, even in
elderly chronic stroke patients with concomitant vascular disease.
It has to be kept in mind though that only a small number of
patients (n=21 in the G-CSF group) were examined. However,
this safety analysis is the first step on the road to introducing a
novel therapeutic approach to the clinical realm [39].
Given the long-time experience with G-CSF in other indica-
tions, and the strong rationale for G-CSF as a recovery-enhancing
drug it is now the time to initiate adequately powered trials
examining the potential efficacy of this drug in improving
functional outcome in the subacute or chronic stage after stroke.
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